SciFed Journal of Immunology

Potential Role Of B-Cells In Compromizing Graft Outcome In Kidney Transplantation

SciFed Journal of Immunology

Potential Role Of B-Cells In Compromizing Graft Outcome In Kidney Transplantation

Review Article

Received on: January 30, 2017, Accepted on: May 20, 2017, Published on: May 30, 2017

Citation: Ahmed Akl (2017) Potential Role Of B-Cells In Compromizing Graft Outcome In Kidney Transplantation. SF J Immunol 1:1.

Copyright: ©2017 Ahmed Akl. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

  • Author

    Ahmed Akl

    Urology & Nephrology center


Keywords: HLA; B cells; Donor specifc B cells; Beads B cells rosettes; Graft outcome.
Running Title : Graft specifc B cells


            Incremental increase in the frequency of memory vs naïve B cells has been associated with poor long-term allograft survival. Role of graft-specific B cells in chronic allograft rejection is still unknown. Identification of graft specific B cellsis of importance in better understanding the mechanisms of graft lesions, earlier diagnosis of acute &chronic rejection, and to guide specific B cell-targeted therapy. This review article provides overview of research surrounding the importance of graft specifc B cells in kidney transplantation. 

Human Leukocyte Antigen (HLA) Antibodies Post Renal Transplantation 
             Donor specific HLA antibodies have been associated with acute and chronic immunological graft injury [1, 23]. Their correlation carry many pitfalls. When anti-donor antibodies are not detected, it is not clear whether it is because the antibodies quantity are too small,their disappearance from the serum related to their sequestration in the transplanted organ [4], or whether none are produced because of unresponsiveness of the recipient against donor antigens [5,6]. Moreover, it is not unusual to fnd patients who developed antibodies post transplantation demonstrating a decrease in antibody titer up to complete elimination of those antibodies. Such patient generates antibodies rapidly after re-exposure to the sensitizing antigen. Similar observations were seen in multiparous women who developed antibodies at some stage of their lives but later on fadeout despite the clearpresence of quiescence memory cells. Thus, detection of antibodies against HLA in the serum after transplantation depend on a balance between immunogen, antibodies generation, sequestration of the antibodies by the transplanted graft plusblock of antibodies by regulatory factors [7]. 

Identification of HLA specific B cells 
           Memory B cells may be poly-reactive than antibodies produced by Long Lived plasma cells [8]. During a secondary infection, serum could only protect when challenged with a homologous virus, whereas memory B cells could protect against both homologous and heterologous variant virus when challenged. The results from viral studies reflect an important issue in transplantation.First, during pre-transplant preparation step, it suggests that analysis of the reactivity against the donor HLA of sensitized patients using serum alone may be insufficient for optimal HLA matching. Second,after secondary transplantation in sensitized patients, denovo donor specific antibodies (DSA) associated with unpredicted or multiple HLA specifcities may be arising from memory B-cell precursors.
       The ability to detect and identify the specificity of circulating B cells with the potential to make HLA antibodies should provide tool to analyze antibody formation and shed light on the balance between production, inhibition and sequestration at any given time in the post-transplant period. Perry et al. recently reported on an assay to detect in vitro HLA specific antibody secreting cells from the bone marrow of sensitized kidney transplant recipients [9]. T and B-cell ELISPOT have also been used to measure HLA specific B cell frequency against a given antigen. ELISPOT assay does not measure the frequency of cells that actually bind the antigen and only measures biological events such as cytokine release [10] or production of immunoglobulin after differentiation in vitro [11,12]. 
         Based on the structural similarity between B cell receptor and immunoglobulin binding sites, it is postulated that HLA-specific B cells should bind to HLA molecules with specificity comparable to that of the secreted immunoglobulin. Indeed, identification of HLA specifc B cells by staining through binding of the B cell receptor using fluorescently labeled tetramers of identified HLA class I specifcities has been described [13]. A different approach is to utilize commercially available single antigen coated, color-coded microspheres, multiplexed in an assay that is currently the mainstay of soluble antibody detection in the circulation [14, 1516]. However, this powerful assay has also highlighted the challenges of cross- and poly-reactivity of allo-antibodies [17, 18] have recently described a method utilizing single HLA coated beads to enumerate HLA committed B cells [18]. Class I HSB identified in non-transplanted individuals were described by [19] who identified HLA specific B cells using tetramers and of who isolated B cells from blood donors using HLA-A2 tetramers [20]. Up to our knowledge no studies reported identification of HSB class II in transplanted recipients. Frequency of HSB from transplanted recipients was higher than in non-transplanted individuals that has been observed with tetramers studies [21, 22] especially frequency of HSB in the poor outcome group.CD27 [26] and CD38 [23] phenotypes considered markers of memory and transitional immunoglobulin secreting cells among total B cells. An observation of memory B cells depletion following alemtuzumab induction therapy, majority of CD27 positive B cells and CD38hi/IgDhi, CD38+/IgDwere depleted in the 3 months samples compared to pretransplant samples and re-populated at 12 months that was reported by [24] and [25] with alemtuzumab induction therapy. Interestingly, majority of B cells remaining in the memory compartment were HLA specific B cells especially in the group of recipients with poor outcome and that may be because they could escape depletion by induction therapy. [21, 22] reported similar fndings when they identified HLA class I specifc B cells from end-stage renal patients and healthy volunteers using tetramers. While in study majority of HSB identified by HLAcoated beads were within the mature naïve (CD27-IgD+) compartment from fve immunized transplant recipients [18]. A phenomenon of anti-HLA antibodies generation has been described after some bacterial or autoantibodies directed against the heavy chain of soluble HLA-E could explain HLA class I reactivity [26, 27] and even after vaccination [28]. Further, in the case of induction therapy at time of transplantation it has been shown that depletion of T and B cells below certain level can lead to homeostatic proliferation of memory B cells that escape the depletion producing de novo expansion of anti-HLA B cells and production of circulating HLA antibodies that may lead to humoral chronic rejection if the antibodies cross-react with shared epitopes presented by donor graft [29]. 

Management of graft infltrative specifc B cells 
          Understanding the basic biology of B cells allow for use of specific therapeutics for instance, anti-CD20 (Rituximab) successfully control memory and active naive B cell responses, targeting the B cell survival factor with anti-BAFF/BLyS (anti-BAFF; belimumab) reducesmature B cell pool as well germinal center B cell responses, additional inhibition of plasma cells can be achieved by combined inhibition of BAFF and APRIL with TACI-Ig; (atacicept) [30]. Depletion of short-lived antigen specific cells can be achieved with the small molecule inhibitor of proteasome, bortezomib (Velcade), which promotes plasma cell apoptosis and inhibits cell proliferation [31].              
          In conclusion comparable assays are being used to quantify plasma cells and memory B cells specific for HLA or pathogens in transplant patients. These assays will guide clinicians to quantify the effcacy of immunosuppression targeting each B cell or plasma cell subset.


  1. Mizutani K, Terasaki P, Hamdani E, et al. (2007) The importance of anti-HLA-specifc antibody strength in monitoring kidney transplant patients. Am J Transplant 7: 1027–1031.
  2. Mizutani K, Terasaki P, Rosen A, et al. (2005) Serial tenyear follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant 5: 2265–2272.
  3. Tambur AR, Pamboukian SV, Costanzo MR, et al. (2005) The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome. Transplantation 80: 1019–1025.
  4. Heinemann FM, Roth I, Rebmann V, et al. (2006) Characterization of anti-HLA antibodies eluted from explanted renal allografts. ClinTranspl 371–378.
  5. Kawai T, Cosimi AB, Spitzer TR, et al. (2008) HLAmismatched renal transplantation without maintenance immunosuppression. N Engl J Med 358: 353–361.
  6. Madsen JC, Superina RA, Wood KJ, et al. (1988) Immunological unresponsiveness induced by recipient cells transfected with donor MHC genes. Nature 332: 161–164.
  7. Li Y, Ma L, Yin D, et al. (2008) Long-term control of alloreactive B cell responses by the suppression of T cell help. J Immunol 180: 6077–6084.
  8. PurthaWE, Tedder TF, Johnson S, et al. (2011) Memory B cells, but not long-lived plasma cells, possess antigen specifcities for viral escape mutants. J Exp Med 208: 2599.
  9. Perry DK, Pollinger HS, Burns JM, et al. (2008) Two novel assays of alloantibody-secreting cells demonstrating resistance to desensitization with IVIG and rATG. Am J Transplant 8:133– 143.
  10. Klinman D (2008) ELISPOT assay to detect cytokinesecreting murine and human cells. CurrProtocImmunol 6: 6-19.
  11. Bromage E, Stephens R, Hassoun L (2009) The third dimension of ELISPOTs: Quantifying antibody secretion from individual plasma cells. Journal of Immunological Methods 346: 75–79.
  12. Lycke NY, Coico R (2001) Measurement of immunoglobulin synthesis using the ELISPOT assay. CurrProtocImmunol 7: 7-14.
  13. Lucas DP1, Leffell MS, Zachary AA (2013) Tetramer staining for the detection of HLA-specifc B cells. Methods Mol Biol. 1034: 313-318.
  14. El-Awar N, Lee J, Terasaki PI (2005) HLA antibody identifcation with single antigen beads compared to conventional methods. Hum Immunol. 66: 989-997.
  15. Yang CW, Oh EJ, Lee SB (2006) Detection of donor-specifc anti-HLA class I and II antibodies using antibody monitoring system. Transplant Proc 38: 2803-2806.
  16. El-Awar N, Nguyen A, Almeshari K (2013) HLA class II DQA and DQB epitopes: recognition of the likely binding sites of HLA-DQ alloantibodies eluted from recombinant HLA-DQ single antigen cell lines. Hum Immunol. 74: 1141-1152.
  17. Dimitrov JD, Planchais C, Roumenina LT (2013) Antibody polyreactivity in health and disease statuvariabilis. J Immunol. 191: 993-999.
  18. Degauque N, NgonoAE,AklA, et al. (2013) Characterization of antigen-specifc B cells using nominal antigen-coated flowbeads. PLoS One. 8: e84273.
  19. Newman J, Rice JS, Wang C, et al. (2003) Identifcation of an antigen-specifc B cell population. J Immunol Methods 272: 177.
  20. Mulder A, Eijsink C, Kardol MJ, et al. (2003) Identifcation, isolation, and culture of HLA-A2-specifc B lymphocytes using MHC class I tetramers. J Immunol 171: 6599.
  21. Zachary AA1, Kopchaliiska D, Montgomery RA, et al. (2007) HLA-specifc B cells: I. A method for their detection, quantifcation, and isolation using HLA tetramers. Transplantation 83: 982-988.
  22. Zachary AA1, Kopchaliiska D, Montgomery RA (2007) HLA-specifc B cells: II. Application to transplantation. Transplantation 83: 989-994.
  23. Agematsu K, Hokibara S, Nagumo H (2000) Komiyama A. CD27: a memory B-cell marker. Immunol Today. 21: 204-206.
  24. Bohnhorst J, Bjorgan MB, Thoen JE , et al. (2001) Bm1- Bm5 classifcation of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjögren’s syndrome. J Immunol. 167: 3610-3618.
  25. Heidt S, Hester J, Shankar S, et al. (2001) B cell repopulation after alemtuzumab induction-transient increase in transitional B cells and long-term dominance of naïve B cells. Am J Transplant. 12: 1784-1792.
  26. Todeschini M, Cortinovis M, Perico N, et al. (2013) In kidney transplant patients, alemtuzumab but not basiliximab/low-dose rabbit anti-thymocyte globulin induces B cell depletion and regeneration, which associates with a high incidence of de novo donor-specifc anti-HLA antibody development. J Immunol. 191: 2818-2828.
  27. Hirata AA, Terasaki PI (1970 ) Cross-reactions between streptococcal M proteins and human transplantation antigens. Science 168: 1095-1096.
  28. Ravindranath MH, Kaneku H, El-Awar N, et al. (2010) Antibodies to HLA-E in nonalloimmunized males: pattern of HLA-Ia reactivity of anti-HLA-E-positive sera. J Immunol. 185:1935-1948.
  29. Katerinis I, Hadaya K, Duquesnoy R, et al. (2011) antiHLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients. Am J Transplant. 11: 1727-1733.
  30. Stohl W, Hilbert DM (2012) The discovery and development of belimumab: theanti-BLyS-lupus connection. Nat Biotechnol 30: 69.
  31. Ejaz NS, Alloway RR, Halleck F, et al. (2014) Review of bortezomib treatment of antibody-mediated rejection in renal transplantation. Antioxid Redox Signal 21: 2401-2418.